Bionomics initiates phase Ib trial of anxiety drug
03 February, 2015 by Dylan Bushell-EmblingBionomics (ASX:BNO) has commenced a phase Ib trial of BNC210, its anxiety and depression drug candidate, and is laying the groundwork for a phase IIa trial due to begin this quarter.
Avita enrols first patient for key burns trial
30 January, 2015 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) has started recruiting for a phase III trial of ReCell in burn injuries, as part of its application process in the US and by extension the UK.
Foresight to translate research into treatments, devices and diagnostics
29 January, 2015Amid the growing realisation that Australian research needs support to make it a reality, the Queensland Premier has pledged a "centrepiece" $90 million Research to Reality Fund if the LNP is returned in this weekend's election.
ResMed boosts December quarter profit by 5%
29 January, 2015 by Dylan Bushell-EmblingSleep-disordered breathing technology company ResMed (ASX:RMD) has reported a 5% increase in profit and a 10% hike in revenue for the December quarter.
Highlighting the digital health achievements of the sector
27 January, 2015Digital health is one of the strongest trends in healthcare and is transforming the delivery of healthcare around the world, including, but not limited to, digital applications (apps) and wearable technology. AusBiotech members are increasingly developing digital health technologies.
Peter Lewis wins Order of Australia honour
27 January, 2015 by Dylan Bushell-EmblingAustralian biotech veteran Peter Lewis has been named a Member of the Order of Australia for his contribution to international trade, biotech and ICT.
Clinuvel appoints non-executive director
22 January, 2015 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has named B&S International founder William Blijdorp as a non-executive director, to help assist with the European commercialisation of Scenesse in erythropoietic protoporphyria.
Smart inhaler helps asthmatic kids breathe easier
22 January, 2015 by Dylan Bushell-EmblingA smart inhaler developed by Nexus6 improves medication adherence in child asthmatics and reduces their reliance on rescue medication.
Join Australia's pavilion at the China Medical Equipment Fair
22 January, 2015AusBiotech is seeking expressions of interest to join the Australian delegation to the 73rd China International Medical Equipment Fair (CMEF), to be held in Shanghai, China, from 15-18 May 2015.
Pharmaxis inflammatory disease drug enters phase I
22 January, 2015 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has kicked off a phase I single ascending dose study of PXS428A, an SSAO inhibitor with the potential to treat inflammatory diseases including non-alcoholic steatohepatitis.
Medical Developments close to Penthrox approval in UK
21 January, 2015 by Dylan Bushell-EmblingMedical Developments International (ASX:MVP) is close to securing approval from the UK's MHRA for its inhaled analgesic Penthrox.
CEOs' views sought on consultations: share schemes and equity crowd funding
20 January, 2015Among the proposals included in the October release of the federal government's Industry Innovation and Competitiveness Agenda (IICA) was a consultation on a potential regulatory framework for crowd-sourced equity funding (CSEF) in Australia and the tax treatment of employee share schemes (ESS), to be repaired after the 2009 changes saw companies flee the program.
Orthocell wins Chinese patent for Celgro
19 January, 2015 by Dylan Bushell-EmblingOrthocell (ASX:OCC) has been granted a Chinese patent for its Celgro collagen bio-scaffold platform technology, augmenting its IP protection in the APAC region.
Immuron recruiting patients for ASH trial
19 January, 2015 by Dylan Bushell-EmblingImmuron (ASX:IMC) has enrolled the first patients for a phase II trial of IMM-124E in alcoholic steatohepatitis and arranged to potentially license the drug candidate in alcohol-induced liver toxicity.
Novogen claims brain regeneration breakthrough
16 January, 2015 by Dylan Bushell-EmblingNovogen (ASX:NRT) has identified a family of compounds with the potential to promote the growth and activity of stem cells in injured parts of the brain.
